The Effect Model Company

At the intersection between computer science and biomedicine, NOVADISCOVERY has developed an innovative approach which de-risks decision-making across the entire drug development lifecycle: research, clinical studies and market.

A discovery by Prof. Jean Pierre Boissel, a reference in clinical trial methodology and one of the founding fathers of system medicine, forms the cornerstone of its unique approach. Based on the Effect Model law, this approach makes it possible, for the first time, to predict the clinical efficacy of any therapy, at the individual and the population level, and compare it to that of competing products. This methodological standard for in silico trials has received the stamp of approval of major US and European agencies.

Building on top of this industry standard, NOVADISCOVERY has developed the first full-scale predictive analytics platform integrating multi-omics, clinical data and biomedical knowledge to support biopharmaceutical R&D and provide the right drug for the right patient at the right price.

Based in Lyon, France, NOVADISCOVERY brings together a multidisciplinary team of experts (from biology and mathematics to computer science) dedicated to shifting away from the prevailing model, which relies heavily on serendipity and costly trial-and-error, in favor of one driven by mathematics, predictive analytics and computer science.

In this section: